Clinical trial

Prospective cohort study

Environmental health

Population

Obesity

Physical therapy

Weight loss

Internal medicine

Clinical endpoint

Randomized controlled trial

Intention-to-treat analysis

Medicine

The Lancet

ESG is a safe intervention that resulted in significant weight loss, maintained at 104 weeks, with important improvements in metabolic comorbidities. ESG should be considered as a synergistic weight loss intervention for patients with class 1 or class 2 obesity. This trial is registered with ClinicalTrials.gov, NCT03406975.

Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial